Mobile Menu
Deals & Transactions

Conyers advises Urovant Sciences Ltd. on its US$140 million initial public offering

Conyers Dill & Pearman advised Urovant Sciences Ltd. (“Urovant”) on its initial public offering of 10,000,000 common shares at a price to the public of US$14.00 per share, for total gross proceeds of US$140 million. Urovant has granted the underwriters a 30-day option to purchase up to 1,500,000 additional common shares at the initial public offering price, less the underwriting discounts and commissions.

Urovant is a clinical-stage biopharmaceutical company focused on developing therapies for urologic conditions.

Director Neil Henderson and Associate Robert Alexander of Conyers’ Bermuda office advised on the matter.


Neil Henderson

Bermuda   +1 441 298 7846


"Few firms can come close to Conyers on one critical metric, and this is the breadth of the client base."
- IFLR1000